Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Nebivolol a) attenuates the angiotensin II (Ang II)-induced increase in oxidative stress, thereby attenuating Ang II-induced vasoconstriction; and b) attenuates sympathetic mediated vasoconstriction during exercise, thereby reducing functional skeletal muscle ischemia in hypertensive patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: Forest Laboratories
• Treatments: Angiotensin II; Angiotensinogen; Giapreza; Metoprolol; Nebivolol; Polystyrene sulfonic acid

Criteria

Inclusion Criteria:

• Stage I hypertension (140-159/90-99 mmHg)

• Men and women age 18-65

Exclusion Criteria:

• Congestive heart failure or coronary artery disease

• Blood pressure averaging >159/99 mmHg or resting heart rate < 55 bpm

• Serum creatinine > 1.4 mg/dL

• Asthma or chronic obstructive pulmonary diseases

• Left ventricular hypertrophy by echocardiography or ECG

• Pregnancy

• Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin

• Any history of substance abuse (other than tobacco)

• Concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)

• History of symptomatic bradycardia or heart block